Menopause Blood Test UK: Which Hormones to Check, What Results Mean & When Testing Actually Helps

1. What is menopause — and what is perimenopause?

Menopause is defined as 12 consecutive months without a period, marking the end of ovarian reproductive function. The average age in the UK is 51, but it can occur naturally anywhere between 45 and 55. Early menopause (40–45) and premature ovarian insufficiency (under 40) affect approximately 1 in 100 women under 40 and have distinct diagnostic and treatment implications.

Perimenopause is the transition phase — typically 4 to 8 years before the final period, though it can last up to 14 years. During this time, the ovaries produce fluctuating and gradually declining levels of oestrogen and progesterone. These hormonal swings drive the familiar symptoms: hot flushes, night sweats, sleep disruption, brain fog, mood changes, joint pain, irregular periods, and reduced libido.

The key clinical distinction: menopause is a retrospective diagnosis (you only know you've reached it after 12 months without a period), while perimenopause is an active, fluctuating process. This difference matters enormously for blood testing, because hormone levels during perimenopause are inherently unstable.

2. Which hormones does a menopause blood test check?

A comprehensive menopause panel typically includes six markers. The NHS will usually only test one or two (FSH and sometimes thyroid) if they test at all. A private panel gives you the full picture.

A Helvy Hormone panel includes all six markers plus SHBG, testosterone, and DHEA-S for a complete hormonal picture.

3. FSH: the primary menopause marker

Follicle-stimulating hormone (FSH) is produced by the pituitary gland to stimulate the ovaries to develop follicles and produce oestrogen. As ovarian function declines, the pituitary increases FSH output — essentially “shouting louder” at ovaries that are responding less.

An FSH level above 30 IU/L on a blood test taken on day 2–5 of the menstrual cycle strongly suggests perimenopause or menopause. The postmenopausal reference range is 30–118 IU/L according to NHS pathology laboratories.

However, FSH has a critical limitation: during perimenopause, it fluctuates enormously. A woman might have an FSH of 45 IU/L one week and 12 IU/L the next, because the ovaries still produce bursts of oestrogen intermittently. A single “normal” FSH does not rule out perimenopause.

For suspected premature ovarian insufficiency (POI) — menopause before age 40 — NICE recommends two FSH samples taken 4–6 weeks apart, both showing elevated levels, before confirming the diagnosis.

4. Oestradiol (E2): why it falls and what that means

Oestradiol is the most potent form of oestrogen and the primary hormone driving menstrual cycles, bone density, cardiovascular protection, skin elasticity, mood regulation, and cognitive function. During perimenopause, oestradiol production becomes erratic before declining permanently.

Postmenopausal oestradiol typically falls below 100 pmol/L. But during perimenopause, levels can spike to supraphysiological highs (sometimes above 1,000 pmol/L) before crashing — this hormonal volatility drives many of the most disruptive symptoms.

Oestradiol is particularly important for women on HRT, where monitoring ensures adequate replacement. The British Menopause Society recommends a target oestradiol of 200–600 pmol/L on HRT, with levels above 200 pmol/L necessary for bone protection.

When testing oestradiol on HRT, timing matters: test before applying your next patch or at least 4 hours after gel application to capture the trough level, not the peak.

5. AMH: predicting when menopause will arrive

Anti-Müllerian hormone (AMH) is produced by developing ovarian follicles and declines steadily with age, becoming undetectable near menopause. Unlike FSH and oestradiol, AMH is relatively stable across the menstrual cycle and is not affected by hormonal contraception — making it a uniquely useful marker.

Research published in the Journal of Clinical Endocrinology & Metabolism has shown that AMH can predict the approximate time to menopause with reasonable accuracy. A 2023 systematic review found that an AMH below 0.25 ng/mL (1.78 pmol/L) was diagnostic of premature ovarian insufficiency with 92% sensitivity.

AMH is most valuable for women under 40 with a family history of early menopause, women considering fertility preservation, and anyone wanting a proactive baseline of their ovarian reserve. It tells you how many eggs you have left — not how good they are, but how much runway remains before menopause.

The NHS does not routinely test AMH outside fertility clinics. This is one of the clearest gaps that private blood testing fills.

6. Thyroid: the great symptom mimic

Hypothyroidism and perimenopause share an extraordinary number of symptoms: fatigue, weight gain, brain fog, mood changes, hair thinning, cold intolerance, irregular periods, and joint pain. Women in their forties are at peak risk for autoimmune thyroid disease, and it is easily missed when symptoms are attributed to “just menopause.”

A simple TSH and Free T4 blood test rules thyroid dysfunction in or out within 48 hours. If your TSH is elevated (above 4.0–4.5 mU/L) or your Free T4 is low, the cause of your symptoms may be thyroid — not menopause — and the treatment is completely different.

Any menopause blood panel worth the name should include thyroid markers. Diagnosing menopause without excluding thyroid disease is like diagnosing a flat tyre without checking the other three.

7. Reference ranges: premenopause vs perimenopause vs postmenopause

These ranges are from NHS pathology laboratories and represent population-level reference intervals for non-pregnant women. Individual results should always be interpreted alongside symptoms.

Perimenopause is characterised by fluctuating levels — a single result may fall anywhere within or outside these ranges. Trends over multiple tests are more informative than any single snapshot.

8. What NICE NG23 says about testing — and why it matters

The NICE NG23 guideline on menopause is the framework most NHS GPs follow. Its recommendations on blood testing are specific and sometimes surprising:

The logic behind NICE's position is sound: for women over 45 with classic symptoms, a blood test adds cost without changing the treatment plan. The GP will offer HRT based on symptoms regardless. But this one-size approach creates genuine blind spots — particularly for younger women, women on contraception, and women whose symptoms could be thyroid-related.

9. Why a single blood test can be misleading in perimenopause

This is the single most important thing to understand about menopause blood testing: during perimenopause, your hormones are in flux. FSH can swing from menopausal to premenopausal range within the same week. Oestradiol can spike to supraphysiological levels one day and crash the next.

A blood test taken on a “good hormone day” may come back completely normal, leading your GP to conclude that nothing is wrong — even as you experience debilitating symptoms the very next day. This is exactly why NICE says not to rely on blood tests for women over 45: a negative result can be falsely reassuring.

This does not mean blood tests are useless. It means they need to be interpreted in context. A single elevated FSH strongly suggests perimenopause, but a single normal FSH does not rule it out. If your symptoms are consistent with perimenopause and your initial blood test is “normal,” the recommendation is to either diagnose based on symptoms or retest in 4–6 weeks.

A “normal” FSH during perimenopause is like checking the weather at 9am and concluding it won't rain all day. The snapshot may be accurate; the forecast is not.

Serial testing — checking hormones at 6–12 week intervals — gives a far more reliable picture than any single blood draw. Private testing makes this economically viable in a way that the NHS pathway does not.

10. When private blood testing genuinely helps

Private menopause blood testing is not for everyone — if you are over 45 with classic symptoms, your GP should offer HRT without hesitation. But there are six scenarios where private testing fills a genuine gap:

1. Under 45 and your GP dismisses your symptoms. NICE says FSH should be considered at 40–45, but many GPs still refuse. A private test gives you objective evidence to bring back.
2. On hormonal contraception. The pill, patch, ring, and hormonal IUD all mask menopause symptoms and suppress FSH, creating a diagnostic blind spot. Coming off contraception to test is an option — but AMH (unaffected by contraception) can provide ovarian reserve information without stopping.
3. Symptoms that could be thyroid. If your GP tests only FSH and it comes back normal, thyroid dysfunction could still be the cause. A comprehensive panel including TSH, Free T4, and Free T3 rules this out definitively.
4. Family history of early menopause or POI. A proactive AMH and FSH baseline in your thirties can flag declining ovarian reserve years before symptoms appear, giving time for fertility planning.
5. HRT is not working. If you are on oestrogen patches or gel and still symptomatic, checking your serum oestradiol can reveal whether the dose is adequate or absorption is poor.
6. You want a baseline before symptoms start. Knowing your FSH, oestradiol, and AMH in your late thirties or early forties gives you a personal reference point, not a population average, to compare against when symptoms do appear.

11. Blood tests for HRT monitoring

NICE does not mandate routine blood monitoring on HRT, but the British Menopause Society recommends considering serum oestradiol if symptoms persist despite HRT, to check whether the dose is adequate and the delivery method is working.

The review schedule recommended by BMS: initial follow-up at 3 months (to assess efficacy and tolerability), then at 6 months, then annually. At each review, check symptoms, side effects, and whether blood tests are indicated.

Oestradiol below 200 pmol/L on HRT may explain persistent symptoms and inadequate bone protection. Above 600 pmol/L is rarely necessary and may indicate excessive dosing. Testing removes the guesswork.

12. GP blood test vs Helvy: what's the difference?

If your GP offers to test and refers promptly, take it — it's free and clinically valid. Private testing is most valuable when the NHS pathway is slow, incomplete, or when you need serial monitoring that the system doesn't accommodate.

13. Common result patterns and what they mean

14. Frequently asked questions